Fernando De la Garza-Salazar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernando De la Garza-Salazar has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
9 shared publications - Perla Rocío Colunga Pedraza
Servicio de Hematología, Hospital Universitario Dr José Eleuterio González, UANL, Monterrey, Mexico
8 shared publications - Andrés Gómez-De León
Hematology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autonoma de Nuevo León, Monterrey, Mexico
6 shared publications - Olga Graciela Cantú-Rodríguez
Hematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico
6 shared publications - Arnulfo González-Cantú
Research Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza 66450, Nuevo León, Mexico
4 shared publications - César Homero Gutiérrez-Aguirre
Universidad Autónoma de Nuevo León, Servicio de Hematología, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley
Different reductions, different burdens of proof: a framework for drug-sparing levers in anticancer therapy
Aim: Strategies that reduce the drug a regimen acquires are often reported together despite making different pharmacological claims. We developed a framework that decomposes the drug acquired per cycle into five levers — boosting, exposure-lowering dose reduction, duration, frequency and waste — and classifies each by the evidence its claim requires: exposure for boosting, effect for the rest. Methods: Applicability was mapped across venetoclax, ibrutinib, nivolumab and ruxolitinib from pharmacodynamic driver, metabolism, formulation and the regimens in which each lever has been reported. Venetoclax was then developed as a worked acquisition-cost example using publicly reproducible prices from four acquisition settings. Results: No molecule admitted every lever, and what governed each differed by lever: metabolism for boosting, formulation for waste, regimen and indication for duration and frequency. Boosting applied to venetoclax, with caveats to ibrutinib and ruxolitinib, and not to nivolumab. Applicability did not mean a sanctioned regimen achieves its claim: the 70 mg specified with posaconazole leaves exposure approximately twofold that of standard dosing. A 400-to-100-mg adjustment with a strong CYP3A4 inhibitor gave an algebraically fixed 75% reduction in drug acquisition cost, though one branded inhibitor increased cost by 32%. Reduction to 100 mg with and without a booster differed by $39 per cycle, yet the two regimens make different claims. Conclusion: Drug-sparing levers do not carry the same evidentiary burden. Once the pharmacological levers are exhausted, the price of the drug itself remains the dominant determinant of acquisition cost.
- 5 November 2026
- Published by Wiley
Open AccessDifferent reductions, different burdens of proof: a framework for drug-sparing levers in anticancer therapy
Aim: Strategies that reduce the drug a regimen acquires are often reported together despite making different pharmacological claims. We developed a framework that decomposes the drug acquired per cycle into five levers — boosting, exposure-lowering dose reduction, duration, frequency and waste — and classifies each by the evidence its claim requires: exposure for boosting, effect for the rest. Methods: Applicability was mapped across venetoclax, ibrutinib, nivolumab and ruxolitinib from pharmacodynamic driver, metabolism, formulation and the regimens in which each lever has been reported. Venetoclax was then developed as a worked acquisition-cost example using publicly reproducible prices from four acquisition settings. Results: No molecule admitted every lever, and what governed each differed by lever: metabolism for boosting, formulation for waste, regimen and indication for duration and frequency. Boosting applied to venetoclax, with caveats to ibrutinib and ruxolitinib, and not to nivolumab. Applicability did not mean a sanctioned regimen achieves its claim: the 70 mg specified with posaconazole leaves exposure approximately twofold that of standard dosing. A 400-to-100-mg adjustment with a strong CYP3A4 inhibitor gave an algebraically fixed 75% reduction in drug acquisition cost, though one branded inhibitor increased cost by 32%. Reduction to 100 mg with and without a booster differed by $39 per cycle, yet the two regimens make different claims. Conclusion: Drug-sparing levers do not carry the same evidentiary burden. Once the pharmacological levers are exhausted, the price of the drug itself remains the dominant determinant of acquisition cost.
- 7 October 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- p. 1-17
Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and intensive chemotherapy has long been the standard of care for patients fit enough to receive it [1]. For older or comor...
- 7 October 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- p. 1-17
Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and intensive chemotherapy has long been the standard of care for patients fit enough to receive it [1]. For older or comor...
- 2 September 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Impact of Graft-versus-Host Disease on Relapse and Survival in Adults With B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Plus Post-Transplant Cyclophosphamide in Resource-Limited Settings
- 2 September 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Impact of Graft-versus-Host Disease on Relapse and Survival in Adults With B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Plus Post-Transplant Cyclophosphamide in Resource-Limited Settings
- Open Access
- 30 July 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4)
Improving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting
- 30 July 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4)
Open AccessImproving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting
- 7 June 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (10) , 1-3
Intentional CYP3A4 inhibition in venetoclax-based AML therapy: from incidental observation to validated clinical strategy
- 7 June 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (10) , 1-3
Intentional CYP3A4 inhibition in venetoclax-based AML therapy: from incidental observation to validated clinical strategy
- Open Access
- 28 December 2025
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 31 (1) , e70147
Beyond Voltage: Independent Validation of the SV3 + SV4 Criterion for LVH Detection
- 28 December 2025
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 31 (1) , e70147
Open AccessBeyond Voltage: Independent Validation of the SV3 + SV4 Criterion for LVH Detection
- 29 November 2025
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 51 (1) , 5-16
From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies
Intentional cytochrome P450 (CYP) inhibition has been proposed as a pharmacoeconomic strategy capable of reducing oncology drug costs (33–90%) while maintaining clinical efficacy. While the pharmacokinetic effects of CYP inhibition have long been recognized in antiviral and transplant medicine, recent clinical applications in oncology and haematology—particularly in cost-constrained settings—highlight its broader translational potential. Synthetic (e.g. ketoconazole, itraconazole) and natural inhibitors (e.g. grapefruit juice, curcumin) provide feasible pharmacologic options adaptable to varied healthcare infrastructures. Applications may extend beyond oncology to infectious diseases, immunosuppressive therapies, and other specialities. Despite regulatory and safety challenges—including pharmacogenomic variability and special population risks—clear frameworks are urgently needed to distinguish beneficial from hazardous interactions. Broader multicentre trials and ethical policy integration are required to establish intentional CYP inhibition as a validated global model of therapeutic equity and healthcare innovation.
- 29 November 2025
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 51 (1) , 5-16
From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies
Intentional cytochrome P450 (CYP) inhibition has been proposed as a pharmacoeconomic strategy capable of reducing oncology drug costs (33–90%) while maintaining clinical efficacy. While the pharmacokinetic effects of CYP inhibition have long been recognized in antiviral and transplant medicine, recent clinical applications in oncology and haematology—particularly in cost-constrained settings—highlight its broader translational potential. Synthetic (e.g. ketoconazole, itraconazole) and natural inhibitors (e.g. grapefruit juice, curcumin) provide feasible pharmacologic options adaptable to varied healthcare infrastructures. Applications may extend beyond oncology to infectious diseases, immunosuppressive therapies, and other specialities. Despite regulatory and safety challenges—including pharmacogenomic variability and special population risks—clear frameworks are urgently needed to distinguish beneficial from hazardous interactions. Broader multicentre trials and ethical policy integration are required to establish intentional CYP inhibition as a validated global model of therapeutic equity and healthcare innovation.
- Open Access
- 6 November 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (1)
Outpatient low-dose venetoclax-azacitidine vs intensive therapy in newly diagnosed AML in resource-limited settings
- 6 November 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (1)
Open AccessOutpatient low-dose venetoclax-azacitidine vs intensive therapy in newly diagnosed AML in resource-limited settings
- Open Access
- 17 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334829
Clinically interpretable electrovectorcardiographic machine learning criteria for the detection of echocardiographic left ventricular hypertrophy
Echocardiographic left ventricular hypertrophy (Echo-LVH) is frequently underdetected by traditional electrocardiogram (ECG) criteria due to limited sensitivity. We investigated whether integrating ECG with vectorcardiography (VCG) using a clinically interpretable machine learning algorithm (C5.0) could improve diagnostic performance. We analyzed ECG and VCG data from 664 patients, 42.8% of whom had Echo-LVH. The study introduced three new criteria—Marcos VCG, Marcos VCG-ECG, and Marcos VCG-ECGsp—named in honor of the software used for VCG synthesis, and compared their diagnostic performance against 23 established ECG criteria, including Cornell voltage, Peguero-Lo Presti, and Sokolow-Lyon. Marcos VCG-ECGsp, optimized for higher specificity, was included to evaluate trade-offs in performance. Validation was performed using train/test split and 10-fold cross-validation. Marcos VCG-ECG achieved higher AUC than Cornell voltage in both training (0.81 vs. 0.68, p < 0.0001) and testing (0.78 vs. 0.69, p = 0.04). The new criteria also showed superior sensitivity compared to Peguero-Lo Presti, the most sensitive traditional criterion (73.1%, 62.4%, 55.9% vs. 30.1%, p < 0.0001). While specificity was lower than Cornell (81.1% vs. 96.4%, p = 0.017), it remained acceptable, reflecting a clinically relevant trade-off favoring detection over false positives. In conclusion, integrating ECG with VCG through machine learning enances Echo-LVH detection, delivering superior sensitivity while preserving specificity. The proposed criteria are clinically interpretable, highlight the novelty of combining two electrical spectra, and hold potential to impact routine diagnostic practice.
- 17 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334829
Open AccessClinically interpretable electrovectorcardiographic machine learning criteria for the detection of echocardiographic left ventricular hypertrophy
Echocardiographic left ventricular hypertrophy (Echo-LVH) is frequently underdetected by traditional electrocardiogram (ECG) criteria due to limited sensitivity. We investigated whether integrating ECG with vectorcardiography (VCG) using a clinically interpretable machine learning algorithm (C5.0) could improve diagnostic performance. We analyzed ECG and VCG data from 664 patients, 42.8% of whom had Echo-LVH. The study introduced three new criteria—Marcos VCG, Marcos VCG-ECG, and Marcos VCG-ECGsp—named in honor of the software used for VCG synthesis, and compared their diagnostic performance against 23 established ECG criteria, including Cornell voltage, Peguero-Lo Presti, and Sokolow-Lyon. Marcos VCG-ECGsp, optimized for higher specificity, was included to evaluate trade-offs in performance. Validation was performed using train/test split and 10-fold cross-validation. Marcos VCG-ECG achieved higher AUC than Cornell voltage in both training (0.81 vs. 0.68, p < 0.0001) and testing (0.78 vs. 0.69, p = 0.04). The new criteria also showed superior sensitivity compared to Peguero-Lo Presti, the most sensitive traditional criterion (73.1%, 62.4%, 55.9% vs. 30.1%, p < 0.0001). While specificity was lower than Cornell (81.1% vs. 96.4%, p = 0.017), it remained acceptable, reflecting a clinically relevant trade-off favoring detection over false positives. In conclusion, integrating ECG with VCG through machine learning enances Echo-LVH detection, delivering superior sensitivity while preserving specificity. The proposed criteria are clinically interpretable, highlight the novelty of combining two electrical spectra, and hold potential to impact routine diagnostic practice.